Compounds > 1-methylspermidine
Page last updated: 2024-12-07

1-methylspermidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Methylspermidine: A Polyamine with Research Potential

**1-methylspermidine (1-MSP)** is a natural polyamine that is a derivative of the ubiquitous polyamine spermidine. It is found in various living organisms, including bacteria, plants, and animals, and its levels fluctuate with age and disease states.

**Here's what makes it interesting for research:**

* **Potent biological activity:** 1-MSP has a wide range of biological effects, including:
* **Antioxidant properties:** It can protect cells from oxidative stress, which plays a role in aging and disease.
* **Anti-inflammatory properties:** It can suppress inflammation, potentially reducing the severity of various inflammatory diseases.
* **Neuroprotective effects:** Studies suggest it can protect neurons from damage, potentially benefiting conditions like Alzheimer's disease.
* **Cancer-related activity:** 1-MSP has been shown to inhibit tumor growth in some studies.

* **Potential therapeutic applications:** Due to its diverse biological activity, 1-MSP is being investigated as a potential therapeutic agent for a range of diseases, including:
* **Neurodegenerative diseases:** Alzheimer's, Parkinson's, and Huntington's diseases.
* **Cancer:** Several studies are exploring its potential for cancer prevention and treatment.
* **Cardiovascular disease:** 1-MSP's anti-inflammatory and antioxidant properties make it a potential target for heart health improvement.
* **Inflammatory disorders:** Rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
* **Aging:** 1-MSP's ability to combat oxidative stress and inflammation suggests it might play a role in healthy aging.

* **Role in cellular processes:** 1-MSP is involved in various cellular processes, including:
* **Cell growth and proliferation:** It can promote cell division and growth.
* **Gene expression:** 1-MSP can influence the activity of genes involved in cellular processes.
* **Cellular signaling:** It can interact with signaling pathways that regulate various cellular functions.

**Important Research Considerations:**

* **Dosage and delivery:** Determining safe and effective doses of 1-MSP for therapeutic applications requires further research.
* **Mechanisms of action:** Further research is needed to fully understand the mechanisms by which 1-MSP exerts its biological effects.
* **Clinical trials:** While promising in preclinical studies, more clinical trials are needed to evaluate 1-MSP's efficacy and safety in humans.

**In summary, 1-methylspermidine is a naturally occurring polyamine with a wide range of biological activities that makes it a promising target for research in various fields. It holds potential for therapeutic applications in treating a variety of diseases and promoting healthy aging, but more research is needed to fully understand its mechanisms of action and clinical potential.**

1-methylspermidine: RN & structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132108
CHEMBL ID165709
SCHEMBL ID344818
MeSH IDM0197988

Synonyms (13)

Synonym
1-methylspermidine
CHEMBL165709
1-n-(4-aminobutyl)butane-1,3-diamine
1,3-butanediamine, n1-(4-aminobutyl)-, (+-)-
137946-02-2
SCHEMBL344818
150333-68-9
1,8-diamino-5-azanonane
n1-(4-aminobutyl)butane-1,3-diamine
n~1~-(4-aminobutyl)butane-1,3-diamine
DTXSID50929954
EN300-379126
(3-aminobutyl)(4-aminobutyl)amine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID201500Compound level in 96 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 25 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201507Compound level in DFMO-treated SV3T3 cells at 0 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201341Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 1 uM spermidine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85916Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 25 uM 1-methylspermidine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85769Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 10 uM 1,12-dimethylspermine; below detection limits of 0.2 nM/mg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201344Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 1 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201513Compound level in SV3T3 cells after 96 hr; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201349Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 10 uM 1-methylspermine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201503Compound level in DFMO-treated SV3T3 cells after 72 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85925Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 25 uM spermidine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85896Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 10 uM 1-methylspermidine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201361Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 25 uM 1-methylspermine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98234Compound level in DFMO-treated L1210 cells at 0 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201490Compound level in 96 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 10 uM 1,12-dimethylspermine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201358Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 25 uM 1-methylspermidine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85922Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 25 uM 1-methylspermine; below detection limits of 0.2 nM/mg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201498Compound level in 96 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 25 uM 1,12-dimethylspermine; below detection limits of 0.2 nM/mg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98237Compound level in L1210 cells after 72 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85900Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 10 uM 1-methylspermine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85910Compound level in 72 h DFMO (5 mM)-treated HT-29 cells after exposure to 15 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85907Compound level in 72 h DFMO (5 mM)-treated HT-29 cells after exposure to 10 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98085Compound level in 72 hr DFMO (5 mM)-treated L1210 cells after exposure to 10 uM 1-methylspermine; below detection limits of 0.2 nM/mg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85928Compound level in 96 hr DFMO (5 mM)-treated HT-29 cells after exposure to 10 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98079Compound level in 72 hr DFMO (5 mM)-treated L1210 cells after exposure to 10 uM 1-methylspermidine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85904Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 10 uM spermidine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201353Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 10 uM spermidine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201337Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 1 uM 1-methylspermine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98225Compound level in 72 hr DFMO (5 mM)-treated L1210 cells after exposure to 10 uM spermidine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85936Compound level in HT-29 cells after 72 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201488Compound level in 96 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 1 uM 1,12-dimethylspermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201494Compound level in 96 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 10 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID226210Compound level in DFMO-treated HT-29 cells after 96 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201346Compound level in 72 h DFMO (5 mM)-treated SV3T3 cells after exposure to 10 uM 1-methylspermidine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID227374Effect on stimulation of B-Z transition in poly(dG-MedC) at acompound concentration of 1-20 uM; active1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID24565Retention time was determined1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85933Compound level in DFMO-treated HT-29 cells at 0 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201510Compound level in DFMO-treated SV3T3 cells at 96 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98077Compound level in 72 hr DFMO (5 mM)-treated L1210 cells after exposure to 10 uM 1,12-dimethylspermine; below detection limits of 0.2 nM/mg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98230Compound level in DFMO-treated L1210 cells after 72 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85914Compound level in 72 hr DFMO (5 mM)-treated HT-29 cells after exposure to 25 uM 1,12-dimethylspermine; below detection limits of 0.2 nM/mg1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85938Compound level in HT-29 cells after 96 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID85931Compound level in DFMO-treated HT-29 cells after 72 h; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201356Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 10 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID98227Compound level in 72 hr DFMO (5 mM)-treated L1210 cells after exposure to 10 uM spermine; ND denotes no data1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
AID201334Compound level in 72 hr DFMO (5 mM)-treated SV3T3 cells after exposure to 1 uM 1-methylspermidine1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
alpha-Methyl polyamines: metabolically stable spermidine and spermine mimics capable of supporting growth in cells depleted of polyamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (31.58)18.2507
2000's6 (31.58)29.6817
2010's6 (31.58)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.35 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (5.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-butanol
1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.		3.5611alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent
n'-acetylspermine
N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1).		2.0110acetamides;
acetylspermine		human metabolite
putrescine
[no description available]		3.0950alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		10.71191polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		8.5180polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		3.2560alpha-amino acid;
fluoroamino acid		trypanocidal drug
methenamine
Methenamine: An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173). hexamethylenetetramine : A polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms.		2.0110polyazaalkane;
polycyclic cage;
tetramine		antibacterial drug
carbon tetrachloride
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.		2.0510chlorocarbon;
chloromethanes		hepatotoxic agent;
refrigerant
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.4120aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.3920antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		3.5611cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
hypusine
hypusine: N-terminal amino alcohol deriv of Lys occurring in bovine brain & in the urine of children with familial hyperlysinemia; minor descriptor (75-82); online & Index Medicus search LYSINE/AA (75-82). hypusine : An L-lysine derivative that is L-lysine bearing a (2R)-4-amino-2-hydroxybutyl substituent at position N(6).		7.4120
norspermine
3,3,3-tetramine : A polyazaalkane consisting of a 13-membered straight chain alkane with aza-groups at the 1-, 5-, 9- and 13-positions.		1.9910polyazaalkane;
tetramine
mdl 72527
MDL 72527: RN given refers to di-HCl; RN for parent cpd not available 6/85; polyamine oxidase inhibitor		2.4220
1,12-dimethylspermine
1,12-dimethylspermine: RN & structure given in first source; enzyme inducer/activator		7.9240
mdl 73811
MDL 73811: structure given in first source; RN given refers to (Z)-isomer		2.3920
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		01.9810
Leukemia L 1210
[description not available]		02.6730
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Alopecia Circumscripta
[description not available]		02.2510
Alopecia Areata
Loss of scalp and body hair involving microscopically inflammatory patchy areas.		02.2510
Chronic Illness
[description not available]		03.5611
Alopecia Cicatrisata
[description not available]		03.5611
Alopecia
Absence of hair from areas where it is normally present.		03.5611
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.5611
Coagulation Disorders, Blood
[description not available]		02.0510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Acute Edematous Pancreatitis
[description not available]		02.7230
Blood Coagulation Disorders
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.		02.0510
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		02.7230